NCT07176663View on ClinicalTrials.gov

Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure

NANot yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

May 1, 2026

Conditions
Obesity
Interventions
DRUG

Tirzepatide

2.5 mg weekly first month and 5 mg weekly for two month

Trial Locations (1)

1666663421

Nooshin Dalili, Tehran

All Listed Sponsors
lead

Shahid Beheshti University of Medical Sciences

OTHER

NCT07176663 - Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure | Biotech Hunter | Biotech Hunter